RE:RE:RE:The issue of the safe use of higher doses of vaccinia virus July 28, 2022 - Takeda is walking away from the vaccinia virus cancer prospect it picked up in a $120 million deal frome Turnstone Biologics in 2019. Citing “strategic reasons,” the company has terminated the collaboration and returned the global rights for the asset to Turnstone.
In a separate decision to discontinue their collaboration Takeda explicitly referred to "the safety signal" of that investigational agent, however their safety comments could also be viewed as addressing the potential pathogenic issue of an engineered vaccinia virus reverting to its wild state at high doses.
https://www.fiercebiotech.com/biotech/takeda-cuts-ties-cancer-drug-landed-120m-turnstone-deal-part-pipeline-clear-out